Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Short-term Investments (2016 - 2025)

Arcadia Biosciences' Short-term Investments history spans 10 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, Short-term Investments changed N/A year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, changed N/A, while the annual FY2025 figure was $4.3 million, N/A changed from the prior year.
  • Short-term Investments reached $4.3 million in Q4 2025 per RKDA's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $19.1 million in Q1 2021 to a low of $2.6 million in Q3 2024.
  • Average Short-term Investments over 4 years is $5.7 million, with a median of $4.9 million recorded in 2023.
  • Peak YoY movement for Short-term Investments: skyrocketed 526.86% in 2021, then tumbled 49.02% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $19.1 million in 2021, then crashed by 73.16% to $5.1 million in 2023, then plummeted by 49.26% to $2.6 million in 2024, then soared by 65.54% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Short-term Investments are $4.3 million (Q4 2025), $4.8 million (Q3 2025), and $3.1 million (Q2 2025).